NAFLD1
MCID: FTT008
MIFTS: 60

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 56 29 6
Hepatic Steatosis 73 29 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 56 13
Nafld1 56 73
Non-Alcoholic Fatty Liver Disease 1 73
Steatohepatitis 71
Fatty Liver 71

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

31
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 56 613282
MeSH 43 D005234
SNOMED-CT via HPO 68 197321007 442191002
UMLS 71 C0015695 C2711227

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 56 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipodystrophy, congenital generalized, type 1 and familial partial lipodystrophy. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Metabolism and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Entecavir and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and adipocyte, and related phenotypes are hepatic steatosis and homeostasis/metabolism

UniProtKB/Swiss-Prot : 73 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, congenital generalized, type 1 31.5 LEP INS ADIPOQ
2 familial partial lipodystrophy 31.4 RETN LEP INS ADIPOQ
3 abetalipoproteinemia 31.3 PNPLA3 MTTP LEP HADHA
4 acquired generalized lipodystrophy 31.3 RETN LEP ADIPOQ
5 lipodystrophy, familial partial, type 2 31.1 PPARA LEP INS ADIPOQ
6 portal hypertension 30.7 PNPLA3 INS GPT
7 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.4 LEP INS ADIPOQ
8 alcohol use disorder 30.4 SLC17A5 GPT GGT1
9 kwashiorkor 30.4 SLC17A5 INS GPT
10 choline deficiency disease 30.4 PPARA INS GPT
11 cholestasis 30.3 SLC17A5 HADHA GPT GGT1
12 alcoholic hepatitis 30.2 SLC17A5 PNPLA3 GPT GGT1
13 viral hepatitis 30.2 SLC17A5 PNPLA3 INS GPT GGT1
14 bilirubin metabolic disorder 30.2 SLC17A5 GPT GGT1
15 pancreatitis 30.1 SLC17A5 INS GGT1
16 hyperglycemia 30.0 RETN LEP INS ADIPOQ
17 platelet glycoprotein iv deficiency 30.0 PPARA INS
18 esophageal varix 30.0 GPT GGT1
19 reye syndrome 29.9 HADHA GPT
20 glucose intolerance 29.8 RETN LEP INS GPT ADIPOQ
21 gallbladder disease 29.8 INS GPT GGT1
22 placenta disease 29.7 INS HADHA ADIPOQ
23 acute liver failure 29.6 SLC17A5 GPT
24 acute pancreatitis 29.6 RETN INS GPT
25 non-alcoholic steatohepatitis 29.6 PPARA PNPLA3 MTTP INS GPT GGT1
26 fetal macrosomia 29.6 LEP INS
27 alcohol dependence 29.5 SLC17A5 LEP GPT GGT1
28 hyperinsulinism 29.5 RETN PPARA LEP INS ADIPOQ
29 polycystic ovary syndrome 29.4 RETN LEP INS ADIPOQ
30 hypothalamic obesity 29.4 RETN LEP INS
31 hyperuricemia 29.4 LEP INS GPT GGT1
32 acromegaly 29.4 LEP INS ADIPOQ
33 acanthosis nigricans 29.3 PRMT7 LEP INS ADIPOQ
34 familial hypercholesterolemia 29.2 MTTP INS GPT ADIPOQ
35 atherosclerosis susceptibility 29.2 RETN PPARA LEP INS ADIPOQ
36 fatty liver disease 29.2 SLC17A5 RETN PPARA PNPLA3 MTTP LEP
37 vascular disease 29.1 RETN LEP INS ADIPOQ
38 nutritional deficiency disease 29.1 RETN LEP ADIPOQ
39 liver cirrhosis 29.0 SLC17A5 RETN LEP GPT GGT1 ADIPOQ
40 cholelithiasis 29.0 LEP INS GPT GGT1
41 gestational diabetes 29.0 RETN LEP INS ADIPOQ
42 hypothyroidism 28.9 RETN LEP INS GPT ADIPOQ
43 arteries, anomalies of 28.9 LEP INS ADIPOQ
44 hyperthyroidism 28.8 RETN LEP INS GPT
45 chronic kidney disease 28.8 RETN LEP INS FABP1 ADIPOQ
46 leptin deficiency or dysfunction 28.8 RETN PPARA LEP INS ADIPOQ
47 sleep apnea 28.7 RETN LEP INS GPT ADIPOQ
48 lipid metabolism disorder 28.6 RETN PPARA MTTP LEP INS GGT1
49 prediabetes syndrome 28.4 PPARA LEP INS GPT ADIPOQ
50 apnea, obstructive sleep 28.4 RETN LEP INS GPT ADIPOQ

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

31
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 31 HP:0001397

Symptoms via clinical synopsis from OMIM:

56
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic

Clinical features from OMIM:

613282

MGI Mouse Phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 ADIPOQ FABP1 GGT1 HADHA INS LEP
2 adipose tissue MP:0005375 9.87 ADIPOQ INS LEP PNPLA3 PPARA PRMT7
3 liver/biliary system MP:0005370 9.85 ADIPOQ FABP1 HADHA INS LEP MTTP
4 muscle MP:0005369 9.43 ADIPOQ HADHA INS LEP PPARA PRMT7
5 renal/urinary system MP:0005367 9.1 ADIPOQ GGT1 HADHA INS LEP PPARA

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Insulin aspart Approved Phase 4 116094-23-6 16132418
10
Insulin detemir Approved Phase 4 169148-63-4 5311023
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Glucagon Approved Phase 4 16941-32-5
13
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
14
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
19
Zidovudine Approved Phase 4 30516-87-1 35370
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
22
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
23
Tamoxifen Approved Phase 4 10540-29-1 2733526
24
Ergotamine Approved Phase 4 113-15-5 8223
25
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
26
Nortriptyline Approved Phase 4 72-69-5 4543
27
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
32
Lenvatinib Approved, Investigational Phase 4 417716-92-8
33
Metformin Approved Phase 4 657-24-9 14219 4091
34
Dulaglutide Approved, Investigational Phase 4 923950-08-7
35
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
36
Alogliptin Approved Phase 4 850649-61-5 11450633
37
Empagliflozin Approved Phase 4 864070-44-0
38
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
39
Methyltestosterone Approved Phase 4 58-18-4 6010
40
Testosterone enanthate Approved Phase 4 315-37-7 9416
41
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
42
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
43
Zinc Approved, Investigational Phase 4 7440-66-6 32051
44
Insulin glargine Approved Phase 4 160337-95-1
45
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
46
Saxagliptin Approved Phase 4 361442-04-8 11243969
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
48
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735

Interventional clinical trials:

(show top 50) (show all 1294)
# Name Status NCT ID Phase Drugs
1 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
2 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
3 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
6 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
7 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
8 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
9 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
10 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
11 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
12 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
13 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
14 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
15 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
16 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
17 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
18 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
19 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
20 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
21 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
22 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
23 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
24 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
25 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
26 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
27 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
28 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
29 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
30 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
31 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
32 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
33 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
34 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
35 Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A Randomized Clinical Trial Completed NCT02274948 Phase 4 Metformin;Placebo
36 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
37 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
38 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
39 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
40 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
41 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
42 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
43 Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
44 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
45 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
46 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
47 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
48 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
49 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
50 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

40
Liver, Testes, Adipocyte, Kidney, Endothelial, Heart, Ovary

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 9604)
# Title Authors PMID Year
1
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. 56 61
22297845 2012
2
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. 56 61
15565570 2004
3
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. 56
26934227 2016
4
Human fatty liver disease: old questions and new insights. 56
21700865 2011
5
Variant in PNPLA3 is associated with alcoholic liver disease. 56
19946271 2010
6
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. 56
18820647 2008
7
Ethnic differences in the prevalence of cryptogenic cirrhosis. 56
15046220 2004
8
Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. 61 54
20205608 2010
9
Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. 54 61
20216310 2010
10
Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. 54 61
20129611 2010
11
Hepatitis C and hepatic steatosis. 61 54
20139103 2010
12
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. 61 54
20225248 2010
13
Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform [corrected]. 61 54
20195242 2010
14
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. 61 54
20070391 2010
15
Preliminary report: hepatic fat and inflammation in type 2 diabetes mellitus. 61 54
19850309 2010
16
Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. 54 61
19929925 2010
17
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 61 54
19171337 2010
18
Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). 61 54
20178560 2010
19
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. 54 61
20054868 2010
20
The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. 61 54
20476641 2010
21
Hepatic steatosis in a school population of overweight and obese adolescents. 54 61
20151095 2010
22
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. 61 54
19656511 2010
23
Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. 54 61
19809411 2010
24
Animal models for hepatitis C and related liver disease. 54 61
20156300 2010
25
Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. 61 54
20139635 2010
26
Hepatic steatosis in overweight/obese females: new screening method for those at risk. 54 61
19960566 2009
27
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 54 61
19643547 2009
28
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. 54 61
19670414 2009
29
Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. 61 54
19890358 2009
30
Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. 54 61
19752878 2009
31
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 61 54
19474742 2009
32
Therapeutic potential of dithiolethiones for hepatic diseases. 54 61
19563826 2009
33
Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. 54 61
19490416 2009
34
Stearoyl-CoA desaturase inhibitors: update on patented compounds. 61 54
19691439 2009
35
Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. 54 61
19693638 2009
36
Azacycloalkane derivatives as inhibitors of delta-9 stearoyl-coenzyme A desaturase. 54 61
19473107 2009
37
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. 54 61
19475694 2009
38
The emerging role of the endocannabinoid system in cardiovascular disease. 61 54
19357846 2009
39
A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. 61 54
19437491 2009
40
Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. 54 61
19258494 2009
41
Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. 61 54
19608019 2009
42
Exogenous thioredoxin prevents ethanol-induced oxidative damage and apoptosis in mouse liver. 54 61
19205032 2009
43
Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. 61 54
18407527 2009
44
Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. 61 54
19018985 2009
45
Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? 61 54
19291292 2009
46
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. 61 54
19164855 2009
47
Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. 54 61
19141695 2009
48
Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. 54 61
19214024 2009
49
Hepatic steatosis, visceral adiposity, insulin resistance, adiponectin, and inflammation. 54 61
19059541 2009
50
Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. 61 54
19153496 2009

Variations for Fatty Liver Disease, Nonalcoholic 1

ClinVar genetic disease variations for Fatty Liver Disease, Nonalcoholic 1:

6 (show top 50) (show all 86) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRMT7 NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter)SNV Pathogenic 523434 rs1251713297 16:68389688-68389688 16:68355785-68355785
2 PRMT7 NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter)SNV Pathogenic/Likely pathogenic 523435 rs1014959895 16:68363008-68363008 16:68329105-68329105
3 PNPLA3 NM_025225.3(PNPLA3):c.444C>G (p.Ile148Met)SNV drug response 341932 rs738409 22:44324727-44324727 22:43928847-43928847
4 OPA1 NM_001354663.2(OPA1):c.-260_-243deldeletion Conflicting interpretations of pathogenicity 214916 rs863224140 3:193332587-193332604 3:193614798-193614815
5 PNPLA3 NM_025225.3(PNPLA3):c.-44C>GSNV Uncertain significance 341924 rs773713393 22:44319748-44319748 22:43923868-43923868
6 PNPLA3 NM_025225.3(PNPLA3):c.64del (p.His22fs)deletion Uncertain significance 631896 rs765529904 22:44319854-44319854 22:43923974-43923974
7 PNPLA3 NM_025225.3(PNPLA3):c.283C>T (p.Arg95Ter)SNV Uncertain significance 631897 rs753837923 22:44322910-44322910 22:43927030-43927030
8 PNPLA3 NM_025225.3(PNPLA3):c.1186C>T (p.Arg396Ter)SNV Uncertain significance 631898 rs764895790 22:44340644-44340644 22:43944764-43944764
9 PNPLA3 NM_025225.3(PNPLA3):c.1209C>T (p.Pro403=)SNV Uncertain significance 341942 rs184910573 22:44340667-44340667 22:43944787-43944787
10 PNPLA3 NM_025225.3(PNPLA3):c.1340G>A (p.Arg447Gln)SNV Uncertain significance 341944 rs147289545 22:44342156-44342156 22:43946276-43946276
11 PNPLA3 NM_025225.3(PNPLA3):c.*19T>GSNV Uncertain significance 341948 rs569255289 22:44342281-44342281 22:43946401-43946401
12 PNPLA3 NM_025225.3(PNPLA3):c.*71T>GSNV Uncertain significance 341950 rs886057601 22:44342333-44342333 22:43946453-43946453
13 PNPLA3 NM_025225.3(PNPLA3):c.*990T>ASNV Uncertain significance 341962 rs886057604 22:44343252-44343252 22:43947372-43947372
14 PNPLA3 NM_025225.3(PNPLA3):c.*1076C>TSNV Uncertain significance 341964 rs886057605 22:44343338-44343338 22:43947458-43947458
15 PNPLA3 NM_025225.3(PNPLA3):c.*960T>GSNV Uncertain significance 341958 rs886057603 22:44343222-44343222 22:43947342-43947342
16 PNPLA3 NM_025225.3(PNPLA3):c.*1175A>CSNV Uncertain significance 341966 rs529050829 22:44343437-44343437 22:43947557-43947557
17 PNPLA3 NM_025225.3(PNPLA3):c.646A>C (p.Thr216Pro)SNV Uncertain significance 341935 rs35726887 22:44328917-44328917 22:43933037-43933037
18 PNPLA3 NM_025225.3(PNPLA3):c.980-14A>CSNV Uncertain significance 341939 rs781212740 22:44335859-44335859 22:43939979-43939979
19 PNPLA3 NM_025225.3(PNPLA3):c.1419C>T (p.Pro473=)SNV Uncertain significance 341947 rs376208148 22:44342235-44342235 22:43946355-43946355
20 PNPLA3 NC_000022.11:g.43923781C>GSNV Uncertain significance 900687 22:44319661-44319661 22:43923781-43923781
21 PNPLA3 NC_000022.11:g.43923804T>CSNV Uncertain significance 900688 22:44319684-44319684 22:43923804-43923804
22 PNPLA3 NM_025225.3(PNPLA3):c.-69T>CSNV Uncertain significance 900689 22:44319723-44319723 22:43923843-43923843
23 PNPLA3 NM_025225.3(PNPLA3):c.82T>C (p.Cys28Arg)SNV Uncertain significance 902366 22:44319873-44319873 22:43923993-43923993
24 PNPLA3 NM_025225.3(PNPLA3):c.226G>A (p.Ala76Thr)SNV Uncertain significance 902367 22:44322853-44322853 22:43926973-43926973
25 PNPLA3 NM_025225.3(PNPLA3):c.235C>T (p.Arg79Trp)SNV Uncertain significance 902368 22:44322862-44322862 22:43926982-43926982
26 PNPLA3 NM_025225.3(PNPLA3):c.236G>A (p.Arg79Gln)SNV Uncertain significance 902369 22:44322863-44322863 22:43926983-43926983
27 PNPLA3 NM_025225.3(PNPLA3):c.295T>C (p.Cys99Arg)SNV Uncertain significance 903230 22:44322922-44322922 22:43927042-43927042
28 PNPLA3 NM_025225.3(PNPLA3):c.406G>C (p.Asp136His)SNV Uncertain significance 903231 22:44323033-44323033 22:43927153-43927153
29 PNPLA3 NM_025225.3(PNPLA3):c.484G>A (p.Val162Met)SNV Uncertain significance 899623 22:44324767-44324767 22:43928887-43928887
30 PNPLA3 NM_025225.3(PNPLA3):c.494T>C (p.Val165Ala)SNV Uncertain significance 899624 22:44328765-44328765 22:43932885-43932885
31 PNPLA3 NM_025225.3(PNPLA3):c.557C>A (p.Pro186His)SNV Uncertain significance 899625 22:44328828-44328828 22:43932948-43932948
32 PNPLA3 NM_025225.3(PNPLA3):c.599C>T (p.Thr200Met)SNV Uncertain significance 899626 22:44328870-44328870 22:43932990-43932990
33 PNPLA3 NM_025225.3(PNPLA3):c.617A>C (p.Asp206Ala)SNV Uncertain significance 899627 22:44328888-44328888 22:43933008-43933008
34 PNPLA3 NM_025225.3(PNPLA3):c.711A>G (p.Ile237Met)SNV Uncertain significance 900759 22:44330500-44330500 22:43934620-43934620
35 PNPLA3 NM_025225.3(PNPLA3):c.917G>A (p.Arg306His)SNV Uncertain significance 900761 22:44333090-44333090 22:43937210-43937210
36 PNPLA3 NM_025225.3(PNPLA3):c.950T>A (p.Leu317Gln)SNV Uncertain significance 900762 22:44333123-44333123 22:43937243-43937243
37 PNPLA3 NM_025225.3(PNPLA3):c.1091C>G (p.Ser364Cys)SNV Uncertain significance 902434 22:44335984-44335984 22:43940104-43940104
38 PNPLA3 NM_025225.3(PNPLA3):c.1262C>T (p.Pro421Leu)SNV Uncertain significance 902436 22:44342078-44342078 22:43946198-43946198
39 PNPLA3 NM_025225.3(PNPLA3):c.1337C>T (p.Pro446Leu)SNV Uncertain significance 903291 22:44342153-44342153 22:43946273-43946273
40 PNPLA3 NM_025225.3(PNPLA3):c.1338G>A (p.Pro446=)SNV Uncertain significance 903292 22:44342154-44342154 22:43946274-43946274
41 PNPLA3 NM_025225.3(PNPLA3):c.*176G>ASNV Uncertain significance 899690 22:44342438-44342438 22:43946558-43946558
42 PNPLA3 NM_025225.3(PNPLA3):c.*222G>ASNV Uncertain significance 899691 22:44342484-44342484 22:43946604-43946604
43 PNPLA3 NM_025225.3(PNPLA3):c.*346G>ASNV Uncertain significance 899693 22:44342608-44342608 22:43946728-43946728
44 PNPLA3 NM_025225.3(PNPLA3):c.*448C>TSNV Uncertain significance 900835 22:44342710-44342710 22:43946830-43946830
45 PNPLA3 NM_025225.3(PNPLA3):c.*760T>CSNV Uncertain significance 900836 22:44343022-44343022 22:43947142-43947142
46 PNPLA3 NM_025225.3(PNPLA3):c.*812A>GSNV Uncertain significance 900837 22:44343074-44343074 22:43947194-43947194
47 PNPLA3 NM_025225.3(PNPLA3):c.*918G>ASNV Uncertain significance 902513 22:44343180-44343180 22:43947300-43947300
48 PNPLA3 NC_000022.11:g.43923732C>TSNV Uncertain significance 900686 22:44319612-44319612
49 PNPLA3 NM_025225.3(PNPLA3):c.696+12G>ASNV Uncertain significance 900756 22:44328979-44328979 22:43933099-43933099
50 PNPLA3 NM_025225.3(PNPLA3):c.697-5C>ASNV Uncertain significance 900757 22:44330481-44330481 22:43934601-43934601

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

Pathways related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 PPARA PNPLA3 MTTP INS HADHA GPT
2
Show member pathways
12.5 RETN LEP INS ADIPOQ
3
Show member pathways
12.49 PPARA LEP HADHA FABP1 ADIPOQ
5 11.52 LEP INS ADIPOQ
6 11.32 PPARA FABP1 ADIPOQ
7 11.22 RETN PPARA PNPLA3 LEP INS ADIPOQ
8 11.17 PPARA LEP ADIPOQ
9 10.93 PPARA FABP1
10 10.89 LEP ADIPOQ
11 10.86 PNPLA3 GGT1
12 10.8 LEP ADIPOQ
13 10.73 LEP INS
14 10.61 INS GPT

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Biological processes related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.8 PPARA PNPLA3 MTTP LEP HADHA
2 fatty acid metabolic process GO:0006631 9.79 PPARA HADHA GGT1
3 response to hypoxia GO:0001666 9.77 PPARA LEP ADIPOQ
4 glucose homeostasis GO:0042593 9.71 LEP INS ADIPOQ
5 cellular response to insulin stimulus GO:0032869 9.67 LEP GPT ADIPOQ
6 circadian rhythm GO:0007623 9.65 MTTP LEP ADIPOQ
7 spliceosomal snRNP assembly GO:0000387 9.62 PRMT7 GGT1
8 negative regulation of blood pressure GO:0045776 9.61 PPARA ADIPOQ
9 triglyceride catabolic process GO:0019433 9.59 PNPLA3 FABP1
10 lipoprotein metabolic process GO:0042157 9.58 PPARA MTTP
11 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 LEP INS
12 negative regulation of gluconeogenesis GO:0045721 9.57 INS ADIPOQ
13 positive regulation of gluconeogenesis GO:0045722 9.56 PPARA GPT
14 positive regulation of cellular protein metabolic process GO:0032270 9.55 INS ADIPOQ
15 response to nutrient levels GO:0031667 9.54 PPARA LEP ADIPOQ
16 intestinal absorption GO:0050892 9.52 LEP FABP1
17 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.51 PPARA ADIPOQ
18 glucose metabolic process GO:0006006 9.5 LEP INS ADIPOQ
19 negative regulation of appetite GO:0032099 9.46 PPARA LEP
20 positive regulation of fatty acid beta-oxidation GO:0032000 9.43 PPARA FABP1
21 negative regulation of feeding behavior GO:2000252 9.26 RETN INS
22 positive regulation of fatty acid metabolic process GO:0045923 9.16 PPARA ADIPOQ
23 fatty acid beta-oxidation GO:0006635 9.13 LEP HADHA ADIPOQ
24 response to insulin GO:0032868 8.92 RETN PPARA LEP HADHA

Molecular functions related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.96 PPARA FABP1
2 hormone activity GO:0005179 8.92 RETN LEP INS ADIPOQ

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....